Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 122 for:    ZOLPIDEM AND Central Nervous System Depressants

Zolpidem or Exercise for Insomnia?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03160404
Recruitment Status : Recruiting
First Posted : May 19, 2017
Last Update Posted : April 18, 2019
Sponsor:
Information provided by (Responsible Party):
Giselle Soares Passos, Universidade Federal de Goias

Tracking Information
First Submitted Date  ICMJE May 4, 2017
First Posted Date  ICMJE May 19, 2017
Last Update Posted Date April 18, 2019
Actual Study Start Date  ICMJE April 16, 2018
Estimated Primary Completion Date July 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 10, 2018)
Change from baseline polysomographic sleep recording to first night and 6 weeks [ Time Frame: baseline, first night, week 6 ]
Polysomnografic recording include electroencephalogram, electrooculogram, electromyogram, and electrocardiogram. Measurements of air flow (oral and nasal), respiratory effort (thoracic and abdominal), body movement, and oxygen saturation were also taken. The measured variables included total sleep time, sleep efficiency (ratio between total sleep time and total recorded time multiplied by 100), sleep onset latency, wake after sleep onset, arousals, sleep stages (N1, N2 and N3 non-rapid eye movement [non-REM] sleep and REM sleep), latencies for each sleep stage. Two researchers who were blinded to the study design performed the staging and analysed the polysomnographic events using international criteria
Original Primary Outcome Measures  ICMJE
 (submitted: May 18, 2017)
  • Sleep onset latency (Polysomnography) [ Time Frame: 12 weeks ]
    minutes
  • Sleep efficiency (Polysomnography) [ Time Frame: 12 weeks ]
    percentage
  • Wake after sleep onset (Polysomnography) [ Time Frame: 12 weeks ]
    minutes
  • Total sleep time (Polysomnography) [ Time Frame: 12 weeks ]
    hours
  • Sleep stages - REM AND NON REM (N1-3) Polysomnography [ Time Frame: 12 weeks ]
    minutes
  • Sleep onset latency (sleep diary scale) [ Time Frame: 12 weeks ]
    minutes
  • Sleep Efficiency (Sleep diary scale) [ Time Frame: 12 weeks ]
    percentage
  • Total Sleep Time (Sleep diary scale) [ Time Frame: 12 weeks ]
    hours
  • Wake after sleep onset (Sleep diary scale) [ Time Frame: 12 weeks ]
    minutes
  • Total Sleep Time (Actigraphy) [ Time Frame: 12 weeks ]
    hours
  • Wake after sleep onset (Actigraphy) [ Time Frame: 12 weeks ]
    minutes
  • Sleep onset latency (Actigraphy) [ Time Frame: 12 weeks ]
    minutes
  • Sleep efficiency (Actigraphy) [ Time Frame: 12 weeks ]
    percentage
Change History Complete list of historical versions of study NCT03160404 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 10, 2018)
  • Change from baseline actigraphy sleep recording to first night and 6 weeks [ Time Frame: baseline, first night, week 6 ]
    It is an objective method to evaluate sleep by movement monitoring during the night. A wrist-watch-like package is used during at least one week. Measures include sleep onset latency, wakefulness after sleep onset, time in bed (TIB), total sleep time (TST), sleep efficiency (SE), and daytime napping. The device is used to assess sleep continuously during 10-day.
  • Change from baseline sleep diary recording to first night and 6 weeks [ Time Frame: baseline, first night, week 6 ]
    The sleep diary was used to evaluate the subjective perceptions of sleep. Participants were instructed to complete the diary every morning after waking for 10 days. The parameters evaluated were sleep onset latency, wake after sleep onset, total time in bed, number of arousals, sleep quality, feeling rested in the morning, and sleep efficiency (calculated retrospectively by the researchers as the ratio of reported total sleep time and reported total time in bed multiplied by 100). These data were averaged for each volunteer for pre- and post-treatment assessment weeks.
  • Change from baseline prior sleep anxiety to first night and 6 weeks [ Time Frame: baseline, first night, week 6 ]
    Prior sleep state anxiety will be assessed with the State-Trait Anxiety Inventory-STAI,25 the Portuguese version of which was validated by Gorenstein and Andrade.26 This scale encompasses 20 items and provides a one-dimensional measurement of anxiety. The volunteers were instructed to answer it 30 minutes before going to sleep at baseline and at the post-exercise evaluation.
  • Change from baseline insomnia severity to 12 weeks [ Time Frame: baseline, week 6 ]
    Insomnia Severity Index (ISI) was administrated at baseline and post treatment to assess insomnia-related complaints. It is a short and easy self-applied scale with 7 items scored from 0 to 4, with a total score varying from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia.
  • Change from baseline sleep quality to 6 weeks [ Time Frame: baseline, week 6 ]
    The PSQI assesses sleep quality over a 1-month period. The questionnaire consists of 19 self-rated questions and 5 questions that should be answered by bedmates or roommates. The latter questions are used only for clinical information. The 19 questions are categorized into 7 components, graded on a score that ranges from 0 to 3. The PSQI components are as follows: subjective sleep quality (C1), sleep latency (C2), sleep duration (C3), habitual sleep efficiency (C4), sleep disturbances (C5), use of sleeping medication (C6) and daytime dysfunction (C7). The sum of scores for these 7 components yields one global score, which ranges from 0 to 21, where the highest score indicates worst sleep quality. A global PSQI score greater than 5 indicates major difficulties in at least 2 components or moderate difficulties in more than 3 components.
  • Change from baseline mood to 6 weeks [ Time Frame: baseline, week 6 ]
    The POMS questionnaire is an instrument to evaluate the acute profile of mood. It has 65 items and 6 domains: tension-anxiety, depression, anger-hostility, vigour-activity, fatigue, and confusion- bewilderment. The total mood disturbance score is derived by subtracting the vigour-activity score from the the sum of scores from the other subscales.
  • Change from baseline quality of life to 6 weeks [ Time Frame: baseline, week 6 ]
    The SF-36 is a multidimensional questionnaire that covers eight components: physical functioning, role limitations due to physical health problems, role limitations due to emotional health problems, social functioning, vitality, general health perception, body pain, and mental health. All scores ranged from 0 to 100, with a higher score indicating better quality of life
  • Change from baseline serum serotonin to first night and 6 weeks [ Time Frame: baseline, first night, week 6 ]
    The serum serotonin dosage will be made by high performance liquid chromatography (HPLC). The blood sample will be collected at 8a.m.
  • Change from baseline cortisol to first night and 6 weeks [ Time Frame: baseline, first night, week 6 ]
    The cortisol dosage will be made by competitive chemiluminescent immunoassay. The blood sample will be collected at 8a.m.
  • Change from baseline Effort Exercise test to 6 weeks [ Time Frame: baseline, week 6 ]
    The test will be performed on a treadmill according to the protocol of Bruce.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 18, 2017)
  • State-Trait Anxiety Inventory [ Time Frame: 12 weeks ]
    scores
  • Profile of Mood States [ Time Frame: 12 weeks ]
    scores
  • Pittsburgh Sleep Quality Index [ Time Frame: 12 weeks ]
    scores
  • Medical Outcomes Study (SF-36) [ Time Frame: 12 weeks ]
    scores
  • Insomnia Severity Index [ Time Frame: 12 weeks ]
    score
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Zolpidem or Exercise for Insomnia?
Official Title  ICMJE The Effects of Zolpidem Compared With Exercise on Chronic Insomnia
Brief Summary

Introduction: The prevalence of chronic insomnia in the general population is between 10 and 15%. The therapy commonly prescribed for its treatment is pharmacological, however, there are several non-pharmacological alternatives being studied, among them physical exercise. Although some studies have described the effect of exercise on sleep in insomnia, there are no studies comparing exercise and drugs in the treatment of chronic insomnia, or its effect as coadjuvant therapy.

Objective: To compare the acute and chronic effects of aerobic exercise and zolpidem on sleep quality, mood and quality of life in patients with chronic insomnia.

Material and Methods: 30 patients with chronic insomnia will be randomly assigned into two groups: EXERCISE (n=15) or ZOLPIDEM (n=15). The patients of EXERCISE group will be included in an aerobic exercise program, performed in 50% of reserve heart rate, on a treadmill (50 minutes, 3 times/week), during 6 weeks. The ZOLPIDEM group will be treated with zolpidem (10mg/night) during 6 weeks. Polysomnography, actigraphy, sleep diary and questionnaires will be used the evaluate sleep pattern. Mood and quality of life will be investigated by POMS and SF-36 questionnaires.

Hypothesis: Considering previous studies have demonstrated positive effects of aerobic exercise in the insomnia symptoms, the hypothesis of this study is that aerobic exercise, performed at moderate intensity, can control the symptoms of chronic insomnia similarly to pharmacological therapy.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Chronic Insomnia
Intervention  ICMJE
  • Drug: Zolpidem
    The ZOLPIDEM group will be treated with zolpidem 10mg/night
  • Behavioral: Exercise
    The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
Study Arms  ICMJE
  • Experimental: EXERCISE
    Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
    Intervention: Behavioral: Exercise
  • Active Comparator: ZOLPIDEM
    10 mg/night during 6 weeks
    Intervention: Drug: Zolpidem
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 10, 2018)
30
Original Estimated Enrollment  ICMJE
 (submitted: May 18, 2017)
45
Estimated Study Completion Date  ICMJE December 30, 2020
Estimated Primary Completion Date July 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  • age 30 -60 years;
  • clinical diagnosis of chronic insomnia according to the DSM-V;
  • insomnia complaint at least 3 times a week for at least 3 months;
  • be physically inactive (exercise less than 2 times a week).

Exclusion criteria:

  • evidence that insomnia is directly related to medical conditions or side effects of medications;
  • obstructive sleep apnea syndrome;
  • ECG abnormalities that prevent physical exercise or use of beta-blockers;
  • uncontrolled clinical diseases (diabetes, hypertension, cardiovascular, neurological or renal diseases);
  • use or history of abuse of alcohol or psychoactive substances);
  • use of sleeping pills> 2 times a week;
  • shift workers.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 30 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: GISELLE PASSOS, PHD 55 64 3606-8304 passos.gs@gmail.com
Listed Location Countries  ICMJE Brazil
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03160404
Other Study ID Numbers  ICMJE 1.986.600
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Giselle Soares Passos, Universidade Federal de Goias
Study Sponsor  ICMJE Universidade Federal de Goias
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Universidade Federal de Goias
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP